Introduction: Chronic atrial fibrillation (AF), coexisting with a history of recent coronary angioplasty with stent (PCI-S) represents an encoded indication for oral anticoagulation with warfarin (OAC) plus dual antiplatelet therapy (DAPT).
INTRODUCTION
A condition commonly found in clinical practice is the coexistence of chronic or persistent atrial fibrillation (AF), which requires oral anticoagulation (OAC) [1] with angina pectoris or acute coronary syndrome (ACS), which requires percutaneous coronary intervention with stenting (PCI-S) [2] , consistently followed by prolonged administration of dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) combined with another suitable platelet antiaggregant (e.g., a thienopyridine such as clopidogrel or prasugrel) [3] . The dual antiplatelet therapy is less effective than the OAC in the conditions where the latter is indicated (e.g., chronic atrial fibrillation) [1] . By contrast, the OAC, even when associated with ASA, is less effective than dual antiplatelet therapy to prevent intra-stent thrombosis or relapses of myocardial ischemia after PCI-S [2] . Thus, *Address for correspondence: Dr. Renato De Vecchis, via P. Gaurico 21, 80125 Napoli, Italy; Tel: +39 3483313530; E-mail: devecchis.erre@virgilio.it, r.de.vecchis@alice.it the combination of OAC and dual antiplatelet therapy, a so-called "triple therapy", would seem to be the most rational solution for patients undergoing PCI-S for acute coronary syndrome or stable effort angina in whom an indication coexists for long-term OAC [4] [5] [6] [7] [8] . However, this triple therapy (TT) with OAC, ASA, and clopidogrel is notoriously regarded to raise the opportunity for bleeding complications [8] [9] . Thus, considering the very feared increase in bleeding inherent in the TT, experimental attempts have been made to reduce the risk of bleeding without diminishing the prophylactic effectiveness against AF-related cardioembolic events by adopting a simplified regimen, i.e., warfarin in combination with a sole antiplatelet agent (clopidogrel or ASA) [8, 10] .
AIM
To make a comparative evaluation of the efficacy and safety endpoints of three different therapeutic strategies adopted within a population of patients, each of whom has a potential indication for both OAC and DAPT.
METHODS
Monocentric case-records of outpatients with AF and history of previous PCI with implantation of one or more bare metal-or drug-eluting stents (either sirolimus or everolimus) were retrospectively examined. The time frame taken into account spans from January 2008 until to December 2013. Data concerning the patients included in our retrospective evaluation were taken from their electronic outpatient folders. Inclusion criterion was the documented indication for prophylaxis of thrombo-embolic events with warfarin (due to chronic or persistent atrial fibrillation, mechanical valve prosthesis, deep vein thrombosis) accompanied by the simultaneous indication in the same patient for prevention of a possible post-procedural intra-stent thrombosis by means of dual antiplatelet therapy (the latter being administered due to recent PCI-S procedure for angina or acute coronary syndrome). Furthermore, for admission into the study, regular administration for an adequate period (not less than 1 month) should have been documented, for one of the following drug regimens: (a) triple therapy (TT) with warfarin plus the combination therapy with ASA and clopidogrel; (b) dual therapy (DT) with warfarin plus either ASA or clopidogrel (i.e., one only of the two above mentioned antiplatelet agents, or (c) dual antiplatelet therapy (DAPT) with ASA and clopidogrel. Furthermore, in the case where AF had been the indication for OAC, patients in whom AF had begun before the coronary stent implantation were considered separately from patients in whom AF had occurred after the stent implantation. Because of the retrospective nature of our study, the investigators did not interfere in the selection of patients assigned to the three treatment regimens. The pharmacologic associations and their doses were determined for each patient, according to the full discretion of the treating physicians and based on criteria that included the patient's general condition, comorbidities, and especially the profiles of both thrombotic and bleeding risk according to the CHA 2 DS 2 -VASc [11] and HAS-BLED [11] scores, respectively. (See explanatory synopses for both the scores shown in Tables 1 and 2 ). The data were meticulously collated and elaborated to build the summarizing tables.
Statistical Analysis
All statistical tests were made with a commercially available statistical analysis program (SPSS 15.0 for Windows, SPSS Inc., Chicago, IL, USA). The distribution of the data was assessed using the D'Agostino-Pearson test. Continuous variables displaying normal distribution were expressed as mean ± SD, while values with asymmetric distribution were expressed as medians with interquartile ranges. Categorical variables were presented as percentages (%). The comparisons were made by means of the one-way analysis of variance (ANOVA) (continuous variables) or by applying the chi-square test (categorical variables). The impact of the three antithrombotic therapies on several outcomes, such as major adverse cardiovascular events (MACEs), total bleeding, major bleeding events, and total events (MACEs plus bleeding) was evaluated with the KaplanMeier method, and differences between treatment groups were estimated with the log-rank test. Ethical approval was not requested, since it is usually not prescribed for retrospective cohort studies in Italy because patients cannot be identified.
RESULTS
98 patients were retrospectively recruited. Their main baseline characteristics are reported in Table 3 . Among them, 48 patients (48.9%) were prescribed TT, 31(31.6%) received DT and 19 (19.4%) were prescribed DAPT. Mean CHADS 2 , CHA 2 DS 2 -VASc, and HAS-BLED scores were 1.8± 1.5, 5.3 ± 1.6, and 2.3 ± 0.5, respectively. After a mean follow-up of 378± 15 days, the absolute rates of MACEs, total bleeding, major bleeding, and total events (MACE plus bleeding) were 21.4%, 18.4%, 7.1%, and 39.8%, respectively. In particular, no significant differences across the three therapy groups were identified for both MACEs and total bleedings ( Table 4 , Figures 1-3) . Likewise, no differences were found in regards to the site of major or minor bleeding across the three therapy categories (Table 5) , except for only genitourinary hemorrhages (a kind of minor bleeding) that exhibited a significant difference in distribution among the three groups (0/48 cases in TT patients, 1/31 cases among DT patients and 3/19 cases among DAPT patients; p[chi -square test]=0.013).Moreover, the lack of significant differences was noticeable in the rate of hemorrhagic relapses by comparing the three therapy groups (Table  5) . Likewise, by using the Kaplan-Meier analysis, no significant differences were observed in the survival free from total MACEs and total bleeding events across the three groups (Figures 4 and 5) .
In our experience, the TT duration never exceeded the limit of three months. Therefore, in our caserecords there were a number of patients for whom dual therapy (DT) was planned as a therapeutic starting strategy (for atrial fibrillation or other conditions entailing thromboembolic risk among patients also requiring simultaneous prophylaxis of intra-stent thrombosis) together with another group of patients, where DT with warfarin plus an antiplatelet drug (ASA or clopidogrel) represented the continuation of the original TT scheme. The therapy was either stopped after one month if a bare metal stent (BMS) had been implanted or was interrupted after a variable period (extending from one to three months) if a drug-eluting stent (DES) had been used. In this scenario, AF cases that occurred after stent implantation (i.e., 20 patients) were significantly less frequent compared to those in which AF occurrence had preceded the percutaneous coronary procedure (i.e., 78 patients) (p [chi square test] <0.0001). However, although the risk of bleeding might appear more pronounced in the cases of AF that had arisen after PCI-S because of the higher expected number of DES implants in this subset and because of the related need for prolonged dual antiplatelet therapy, Legenda: AF, atrial fibrillation; PCI-S, percutaneous coronary intervention with stent implantation.
the incidence of bleeding events in the two subsets was comparable (p=0.9116) (see Table 6 ).
Moreover, importantly, all the 4 major bleeding events reported among patients assigned to TT occurred while administering the triple drug combination. Actually, in regards to the two major bleeding events signaled in the DT group, they involved patients who had been assigned from the first moment to DT, due to their HAS-BLED score that indicated they were at high risk of bleeding. Indeed, bleeding did not occur in cases when DT was administered as a continuation of the original TT after the latter had been stopped. In fact, no case of major bleeding was found in the timeframe subsequent to the switch from TT to DT.
DISCUSSION
The present analysis focused on outpatients, each of whom had experienced a condition requiring oral anticoagulation (OAC) with warfarin (AF, deep venous thrombosis, history of ascertained or suspected cardioembolism, or mechanical cardiac prosthesis). This need for OAC was complicated by the concomitant need for antiaggregant agents, since every patient had recently undergone a PTCA with stent implantation, thus requiring a dual antiplatelet regimen, according to the current guidelines [2] [3] . Therefore, two different scenarios were represented in our study, depending on whether the condition requiring OAC had preceded the stenting procedure or had taken place after the PCI-S.In the first case, (i.e., AF preceding the PCI), the adoption of BMS was consistently preferred on occasion of the subsequent angioplasty with stenting, considering that this type of coronary prosthesis doesn't cause a sustained loss of endothelium, thus requiring a relatively short duration (usually, one month) of the dual antiplatelet therapy (ASA + thienopyridine) for the prophylaxis of intra-stent thrombosis. This is very important because with this method the combined regimen of an anticoagulant joined with a dual antiplatelet treatment is unlikely to generate a high amount of bleeding events, given the relatively short duration (not more than one month) of the dual antiplatelet therapy as scheduled by this protocol. Instead, in the second case, the AF occurs after the patient has already undergone a PCI-S that(in high income countries) generally entails the use of a drug-eluting stent (DES),i.e., a stent that elutes an immunosuppressant drug. In this setting, very challenging problems arise because in the case of DES the prophylaxis of the intra-stent thrombosis with dual antiplatelet therapy should be conducted for at least 12 months [12] [13] , which amplifies the risk that a possible combination regimen comprising the OAC can result in bleeding complications. This concern is the reason for the current trend to maintain TT for a relatively short period (1-3 months in our experience) and then convert it into a less demanding regimen, namely, a hybrid protocol that provides for a single antiplatelet agent (e.g., ASA or clopidogrel) in addition to warfarin or, alternatively, the maintenance of only dual antiplatelet therapy. As presented in the Results,the three antithrombotic regimens of TT, DT, and DAPT that we used in our study exhibited comparable efficacy and safety throughout the prescribed period of follow-up (mean duration among the 98 patients retrospectively examined= 378± 15.7days). The absolute one-year rates of major bleeding with TT, DT, and DAPT were 8.3%, 6.45%, and 5.2%, respectively (p [chi-square test] = 0.893). By comparing the three different therapeutic regimens tested in our study (TT, DT and DAPT), no significant difference was detected regarding the incidence of MACEs (acute coronary syndromes, need for percutaneous or surgical revascularization, or ischemic stroke) or all-cause mortality. In regards to this aspect, the literature data are somewhat contradictory. In fact, based on the results of the ACTIVE-W study [1] , there is documentation of higher efficacy of oral warfarin compared to combination therapy clopidogrel + ASA for the prevention of the ischemic stroke in AF patients. In the above mentioned study, the clopidogrel plus ASA group showed significantly more MACEs, such as stroke, non-central nervous system systemic embolism, myocardial infarction, or vascular death compared to those who received oral warfarin (p=0.0003). Thus, the study was stopped early owing to the clear superiority of the warfarin therapy. By contrast, there are several studies in the literature that demonstrate a substantially comparable preventive efficacy against MACEs exerted by the three abovementioned regimens [8, 14] . Moreover, recent data from the prospective, randomized WOEST study [15] have even shown superior efficacy of DT (with warfarin plus clopidogrel) over TT in regards to the occurrence of MACEs. In addition, in their recent study concerning the prospective, multicenter warfarin and coronary stenting (WAR-STENT) registry, conducted among patients with chronic atrial fibrillation and recent coronary angioplasty with stenting (mostly using bare metal stents), Rubboli et al. [16] detected no evidence of superiority of the TT regimen compared to the simplified scheme consisting of a single antiplatelet agent (ASA or clopidogrel) added to an oral anticoagulant (warfarin). Indeed, in this study, no differences in terms of antithrombotic efficacy were evident, based on the comparison between TT, DT (i.e., warfarin supplemented by either ASA or clopidogrel) and DAPT with ASA and clopidogrel. Furthermore, in the above mentioned study, even an alleged and greatly feared high incidence of major bleeding was not proven in the group of patients assigned to TT scheme. At 12 months, in fact, the frequency of major bleeding events was 4% (14/339 patients), 5% (1/20 patients) and 2% (1/42 patients) in the TT, DT and DAPT groups, respectively.
In patients requiring both the OAC and the prophylaxis of intra-stent thrombosis, our study did not show a superiority of TT regimen compared to alternative schemes consisting of dual antiplatelet therapy or combined administration of warfarin with only one antiplatelet agent with regard to efficacy outcomes (MACEs and mortality from all causes) as well as for the safety endpoints (bleeding events). Therefore, our study adds to the already quite numerous series [8, [14] [15] [16] of preexisting investigations that have disavowed the alleged higher anti-ischemic protection through the practice of adding two, rather than one, antiplatelet agent on top of OAC in patients with atrial fibrillation and recent PCI-S. Really, not even the recent official guidelines provide convincing evidence that triple therapy has better therapeutic efficacy in this clinical setting, considering that European and American position documents categorize recommendations for triple therapy (TT) as "Level of Evidence C" [17] [18] .
STUDY LIMITATIONS
The small sample size and its retrospective observational design are the main limitations of the study. Thus, possible indication biases are likely to have occurred, for example, due to the allocation to the TT group of patients presenting the most severe clinical picture and the highest CHA 2 DS 2 -VASc score. In this way, due to the lack of balance of clinical characteristics across the three groups, the possible higher antithrombotic efficacy of triple therapy may have been hidden or undersized. Moreover, in the present study, the significance of the anti-ischemic protective effect and the potential risk for bleeding of other drug combinations (prasugrel + ASA, ticagrelor + ASA) were not explored, because the data harvested from our outpatient population dates back a few years ago when these novel antiplatelet agents were not used in a routine manner at our Institute, whilst the new oral anticoagulants, alternative to warfarin (dabigatran, rivaroxiban, apixaban, etc.) [19] had not been validated yet for clinical use.
CONCLUSIONS
Based on our retrospective study, the three antithrombotic regimens TT, DT, and DAPT showed comparable efficacy and safety. Further studies with larger sample sizes, preferably modeled as randomized clinical trials, should be planned for comparing the various feasible regimens (with anticoagulant plus single or dual antiplatelet therapy or consisting of the association of two platelet antiaggregants) among patients with indication for OAC and the concomitant need for protection against stent thrombosis due to recent PCI-S.
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